281 related articles for article (PubMed ID: 12721174)
1. Intraperitoneal levonorgestrel-releasing intrauterine device following uterine perforation: the role of progestins in adhesion formation.
Haimov-Kochman R; Doviner V; Amsalem H; Prus D; Adoni A; Lavy Y
Hum Reprod; 2003 May; 18(5):990-3. PubMed ID: 12721174
[TBL] [Abstract][Full Text] [Related]
2. Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study.
Barnett C; Moehner S; Do Minh T; Heinemann K
Eur J Contracept Reprod Health Care; 2017 Dec; 22(6):424-428. PubMed ID: 29322856
[TBL] [Abstract][Full Text] [Related]
3. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
Bosco-Lévy P; Gouverneur A; Langlade C; Miremont G; Pariente A
Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
[TBL] [Abstract][Full Text] [Related]
4. Management of a perforated levonorgestrel-medicated intrauterine device--a pharmacokinetic study: case report.
Haimov-Kochman R; Amsalem H; Adoni A; Lavy Y; Spitz IM
Hum Reprod; 2003 Jun; 18(6):1231-3. PubMed ID: 12773451
[TBL] [Abstract][Full Text] [Related]
5. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
6. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices.
Heinemann K; Reed S; Moehner S; Minh TD
Contraception; 2015 Apr; 91(4):274-9. PubMed ID: 25601352
[TBL] [Abstract][Full Text] [Related]
7. Intrauterine contraception: incidence and factors associated with uterine perforation--a population-based study.
Kaislasuo J; Suhonen S; Gissler M; Lähteenmäki P; Heikinheimo O
Hum Reprod; 2012 Sep; 27(9):2658-63. PubMed ID: 22763376
[TBL] [Abstract][Full Text] [Related]
8. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
9. [Application of levonorgestrel-releasing intrauterine system in early pregnancy: a case report].
Gardyszewska A; Czajkowski K
Ginekol Pol; 2012 Dec; 83(12):950-2. PubMed ID: 23488301
[TBL] [Abstract][Full Text] [Related]
10. Uterine perforation with the levonorgestrel-releasing intrauterine device: analysis of reports from four national pharmacovigilance centres.
van Grootheest K; Sachs B; Harrison-Woolrych M; Caduff-Janosa P; van Puijenbroek E
Drug Saf; 2011 Jan; 34(1):83-8. PubMed ID: 21142273
[TBL] [Abstract][Full Text] [Related]
11. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
[TBL] [Abstract][Full Text] [Related]
12. Complication rates associated with levonorgestrel intrauterine system use in adolescents with developmental disabilities.
Savasi I; Jayasinghe K; Moore P; Jayasinghe Y; Grover SR
J Pediatr Adolesc Gynecol; 2014 Feb; 27(1):25-8. PubMed ID: 24315712
[TBL] [Abstract][Full Text] [Related]
13. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
14. Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users.
Spotnitz ME; Natarajan K; Ryan PB; Westhoff CL
Obstet Gynecol; 2020 Feb; 135(2):319-327. PubMed ID: 31923062
[TBL] [Abstract][Full Text] [Related]
15. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
Heinemann K; Reed S; Moehner S; Minh TD
Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
[TBL] [Abstract][Full Text] [Related]
16. Perforated intraperitoneal intrauterine contraceptive devices: diagnosis, management, and clinical outcomes.
Kho KA; Chamsy DJ
J Minim Invasive Gynecol; 2014; 21(4):596-601. PubMed ID: 24462588
[TBL] [Abstract][Full Text] [Related]
17. Uterine perforation caused by intrauterine devices: clinical course and treatment.
Kaislasuo J; Suhonen S; Gissler M; Lähteenmäki P; Heikinheimo O
Hum Reprod; 2013 Jun; 28(6):1546-51. PubMed ID: 23526304
[TBL] [Abstract][Full Text] [Related]
18. [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].
Yela DA; Monteiro IM; Bahamondes LG; Del Castillo S; Bahamondes MV; Fernandes A
Rev Assoc Med Bras (1992); 2006; 52(1):32-6. PubMed ID: 16622536
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system.
Simonatto P; Bahamondes MV; Fernandes A; Silveira C; Bahamondes L
J Obstet Gynaecol Res; 2016 May; 42(5):554-9. PubMed ID: 26817571
[TBL] [Abstract][Full Text] [Related]
20. Intrauterine device continuation rates and reasons for discontinuation in a Central European clinic with a high standard of care and ultrasound follow-up: a retrospective cohort study.
Bachofner M; Blickenstorfer K; Hutmacher J; Wehrle L; Leeners B; Merki-Feld G
Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):407-414. PubMed ID: 30628516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
